New Zealand Prime Minister Jacinda Ardern receiving her first Pfizer/BioNTech dose, June 18 (Alex Burton/NZ Herald via AP Images)

June 21, 2021 07:46 AM EDTUpdated 11:11 AM

Covid-19 roundup: After winning an EUA, GSK and Vir are back with full data on their monoclonal antibody; New Zealand authorizes Pfizer/BioNTech vaccine for kids as young as 12

Nicole DeFeudis

Editor

Josh Sullivan

A few weeks after snagging an emergency use authorization for their monoclonal antibody sotrovimab based on interim data, GSK and Vir Biotechnology are back with …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Covid-19 roundup: After winning an EUA, GSK and Vir are back with full data on their monoclonal antibody; New Zealand authorizes Pfizer/BioNTech vaccine for kids as young as 12

Nicole DeFeudis

Editor

Josh Sullivan

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

Covid-19 roundup: Af­ter win­ning an EUA, GSK and Vir are back with full da­ta on their mon­o­clon­al an­ti­body; New Zealand au­tho­rizes Pfiz­er/BioN­Tech vac­cine for kids as young as 12

Editor

Sign up to read this article for free.

Covid-19 roundup: After winning an EUA, GSK and Vir are back with full data on their monoclonal antibody; New Zealand authorizes Pfizer/BioNTech vaccine for kids as young as 12